FDA Identifies Aseptic Processing and Sterile Facility Weaknesses

The US Food and Drug Administration (FDA) has highlighted several weaknesses in sterile manufacturing operations, emphasising the importance of robust facility design, effective contamination control and reliable equipment maintenance in aseptic processing.

The concerns were presented by Jason F. Chancey, a consumer safety officer in the FDA’s Center for Drug Evaluation and Research (CDER), during the 2026 PDA/FDA Joint Regulatory Conference. His presentation examined sterile-facility trends and opportunities for modernisation, combining current manufacturing principles with examples drawn from FDA inspection observations.

Chancey described how modern aseptic facilities increasingly rely on automation, integrated manufacturing operations and physical barriers, including restricted access barrier systems (RABS) and isolators. These approaches are intended to reduce manual intervention and protect sterile products from contamination within critical processing areas.

The presentation also identified maintenance failures that can compromise barrier performance. Examples included damaged or taped gaskets, malfunctioning pressure gauges, discoloured membranes and improperly positioned components. Such deficiencies can undermine the protection provided by otherwise well-designed sterile facilities.

Operational practices were another area of concern. Unnecessary interventions, reaching over exposed equipment and introducing unauthorised access points can weaken Grade A protection and increase the risk of microbial contamination.

The FDA also discussed shortcomings in airflow visualisation studies. Inadequate tracer selection, incorrect placement, unrealistic airflow conditions and unaddressed disturbances may prevent these studies from accurately representing routine manufacturing operations.

A warning-letter case presented during the session described repeated microbial recoveries, delays in equipment leak-test remediation, the use of fibre-shedding materials in ISO 5 areas and weaknesses in biological-indicator validation.

The observations demonstrate the need for manufacturers to maintain effective contamination-control strategies throughout facility design, equipment maintenance and day-to-day aseptic operations.

16-09-2026